Compare · AEMD vs DXCM
AEMD vs DXCM
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 17347.6x AEMD ($1.7M).
- Over the past year, AEMD is down 99.5% and DXCM is down 8.8% - DXCM leads by 90.7 points.
- AEMD has been more active in the news (11 items in the past 4 weeks vs 4 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- DexCom Inc.
- Price
- $0.67-1.12%
- $76.65-1.74%
- Market cap
- $1.7M
- $29.58B
- 1M return
- -65.20%
- +4.76%
- 1Y return
- -99.49%
- -8.79%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 11
- 4
- Recent ratings
- 2
- 25
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest AEMD
- Presenting on Emerging Growth Conference 94 Day 2 on July 16; Register to live stream
- Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
- Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Aethlon Medical Inc.
- SEC Form EFFECT filed by Aethlon Medical Inc.
- Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
- Director Shah Chetan covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 9% to 20,840 units (SEC Form 4) (withholding obligation)
- Director Gikakis Nicolas covered exercise/tax liability with 2,182 shares, decreasing direct ownership by 10% to 20,663 units (SEC Form 4) (tax liability)
- Director Broenniman Edward G covered exercise/tax liability with 1,091 shares, decreasing direct ownership by 5% to 22,363 units (SEC Form 4) (for withholding tax)
- Amendment: SEC Form S-1/A filed by Aethlon Medical Inc.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)